| Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) | ||
| OASIS | Sponsor: ThromboGenics | Year: 2011 |
| This study is designed to assess anatomical and functional outcomes following a single intravitreal injection of ocriplasmin 0.125mg in subjects with symptomatic vitreomacular adhesion (VMA) including macular hole. | ||
| A Phase II Evaluation of Topical NSAIDs in Eyes with Non-central Involved Diabetic Macular Edema | ||
| DRCR Protocol R | Sponsor: DRCR Network | Year: 2011 |
| This study is being conducted to assess the effects of topical nonsteroidal anti-inflammatories (NSAIDs) on macular retinal volume compared with placebo in eyes with non-central DME. This phase II trial may provide proof of concept evidence that topical NSAID treatment can have a beneficial effect on DME and possibly prevent increases in retinal volume or progression of non central-involved DME into the central subfield of the macula. Furthermore, it could determine the correlation between OCT and fundus photographic documentation of progression of DME into the central subfield in this clinical trial setting. | ||
| An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy | ||
| DRCR Protocol N | Sponsor: National Eye Institute | Year: 2010 |
| An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy. This is a prospective, multi-center randomized clinical trial for patients with type 1 or 2 diabetes in which the study eye has vitreous hemorrhage precluding treatment with laser photocoagulation. Study eyes are randomized to intravitreal injection of 0.5mg ranibizumab (Lucentis) at baseline, 4 and 8 weeks versus saline injection at the same time periods. | ||
| An Observational Study in Individuals with Diabetic Retinopathy without Center-Involved DME Undergoing Cataract Surgery | ||
| DRCR Protocol Q | Sponsor: National Eye Institute | Year: 2009 - Recruiting |
| An Observational Study in Individuals with Diabetic Retinopathy without Center-Involved Diabetic Macular Edema Undergoing Cataract Surgery. The objective of the study is to determine the incidence of progression to center-involved macular edema 16 weeks after cataract surgery in eyes with diabetic retinopathy and without definite center-involved DME. All treatment is given at the discretion of the treating physicians. | ||
| A Pilot Study in Individuals with Center-Involved DME Undergoing Cataract Surgery | ||
| DRCR Protocol P | Sponsor: National Eye Institute | Year: 2009 - open |
| A Pilot Study in Individuals with Center-Involved Diabetic Macular Edema Undergoing Cataract Surgery. Observational data is collected for eyes with center-involved DME undergoing cataract surgery with treatment given per investigator discretion, with a goal of determining feasibility of a future randomized trial. | ||
| A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD | ||
| Lucedex | Sponsor: Bay Area Retina Associates | Year: 2007 |
| A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD (Lucedex). A prospective, single masked comparative trial using either combination therapy (group 1): same day combination therapy with 0.05cc intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection for four consecutive months will be compared to monotherapy (group 2): one intravitreal injection of 0.5 mg ranibizumab also given for four consecutive months. These treatments will then be followed by PRN treatment. | ||
| Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration | ||
| PDex | Sponsor: Bay Area Retina Associates | Year: 2006 |
| Combination Triple Therapy (Dexamethasone, Photodynamic Therapy and Lucentis) vs. Lucentis Monotherapy. Patients affected by exudative AMD with subfoveal choroidal neovascularization (CNV) were randomized to one of two groups: Group 1 received ranibizumab monotherapy received injections every four weeks for the duration of the study; and Group 2 received triple therapy initially, followed by intravitreal ranibizumab every four weeks on indication. | ||
| A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration | ||
| siRNA Phase I Study | Sponsor: Quark Pharmaceuticals | Year: 2007 |
| A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD). This study assessed the safety and tolerability of a single intravitreal injection of Sirna-027 (AGN211745) along with anatomical changes in the retina, changes in CNV, and changes in visual acuity. | ||
| A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion | ||
| BRAVO | Sponsor: Genentech | Year: 2007 |
| A Phase III multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion. | ||
| A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion | ||
| CRUISE | Sponsor: Genentech | Year: 2007 |
| A Phase III multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion. | ||
| A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus | ||
| RIDE | Sponsor: Genentech | Year: 2007 |
| A Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab injection in patients with clinically significant macular edema secondary to Type 1 or 2 diabetes mellitus. | ||
| A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus | ||
| RISE | Sponsor: Genentech | Year: 2007 |
| A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RISE). A Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab injection in patients with diabetic macular edema secondary to Type 1 or 2 diabetes mellitus. | ||
| A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) | ||
| SAILOR | Sponsor: Genentech | Year: 2005 |
| A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD). A Phase IIIb, single-masked, 1-year multicenter study of the safety and tolerability of intravitreally administered ranibizumab in subjects with active subfoveal CNV secondary to AMD. | ||
| Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy | ||
| DRCR Protocol J | Sponsor: National Eye Institute | Year: 2007 |
| Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. Study eyes were randomized to one of the following: Intravitreal injection of 0.5 mg ranibizumab (Lucentis) at baseline and 4 weeks; Intravitreal injection of 4 mg triamcinolone acetonide at baseline and sham injection at 4 weeks; Sham injection at baseline and 4 weeks. | ||
| Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema | ||
| DRCR Protocol I | Sponsor: National Eye Institute | Year: 2007 |
| Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema. Study eyes were randomized to one of the following: Group A: Sham injection plus focal (macular) photocoagulation; Group B: 0.5 mg injection of intravitreal ranibizumab plus focal photocoagulation; Group C: 0.5 mg injection of intravitreal ranibizumab plus deferred focal laser photocoagulation; Group D: 4 mg intravitreal triamcinolone plus focal photocoagulation. | ||
| A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) | ||
| DRCR Protocol H | Sponsor: National Eye Institute | Year: 2005-08 |
| A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin). Study eyes were randomized to laser photocoagulation; 1.25mg intravitreal bevacizumab injection at baseline and 6 weeks; 2.5mg intravitreal bevacizumab injection at baseline and 6 weeks; 1.25mg intravitreal bevacizumab injection at baseline and (sham injection at 6 weeks); 1.25mg intravitreal bevacizumab injection at baseline, laser photocoagulation at 3 weeks, and 1.25mg intravitreal bevacizumab injection at 6 weeks. | ||
| A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema | ||
| DRCR Protocol E | Sponsor: National Eye Institute | Year: 2004-07 |
| A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema. Phase 2 randomized, multi-center clinical trial in which one study eye was randomized to focal laser photocoagulation; posterior peribulbar injection of 40mg triamcinolone, anterior peribulbar injection of 20mg triamcinolone, posterior peribulbar injection of 40mg triamcinolone followed after one month by laser, or anterior peribulbar injection of 20mg triamcinolone followed after one month by laser. If both eyes qualified, then one eye received laser and the other eye was randomized to one of the four triamcinolone groups. | ||
| Evaluation of Vitrectomy for Diabetic Macular Edema Study | ||
| DRCR Protocol D | Sponsor: National Eye Institute | Year: 2004-09 |
| Evaluation of Vitrectomy for Diabetic Macular Edema. Prospective nonrandomized treatment study in which vitrectomy was performed by the investigator's usual routine with one year of data collected to provide information on the following outcomes in eyes with diabetic macular edema that undergo vitrectomy: visual acuity, retinal thickening, resolution of traction (if present), surgical complications. | ||
| A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema | ||
| DRCR Protocol B | Sponsor: National Eye Institute | Year: 2004-08 |
| A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema. One study eye was randomly assigned to one of three treatment groups: laser photocoagulation; 1mg intravitreal triamcinolone acetonide injection; or 4mg intravitreal triamcinolone acetonide injection. For patients with two study eyes, the second eye was randomly assigned to one of the two treatments not assigned to the first eye. | ||
| A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema | ||
| DRCR Protocol A | Sponsor: National Eye Institute | Year: 2003-08 |
| Laser Photocoagulation for Diabetic Macular Edema Study. This pilot study compared standard laser treatment with a similar laser treatment that was milder in intensity but greater in number of treatment spots ("mild macular grid" method). | ||
| Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study | ||
| SCORE | Sponsor: National Eye Institute | Year: 2004 |
| Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE). A Phase III Study comparing the efficacy and safety of intravitreal injection of triamcinolone acetonide with stadard care in the treatment of macular edema from retinal vein occlusoin. SCORE included two separate trials: one for eyes with branch retinal vein occlusion and one for eyes with central retinal vein occlusion. | ||
| A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) | ||
| PIER | Sponsor: Genentech | Year: 2005 |
| A Phase IIIb, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects With Subfoveal Choroidal Neovascularization (CNV) With or Without Classic CNV Secondary to Age Related Macular Degeneration. | ||
| A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration | ||
| MARINA | Sponsor: Genentech | Year: 2003 |
| A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration. | ||
| RhuFab V2 Ocular Treatment Combining the Use of Visudyne to Evaluate Safety | ||
| FOCUS | Sponsor: Genentech | Year: 2003 |
| A Phase I/II, Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 in Combination With Verteporfin (Visudyne(R)) Photodynamic Therapy in Subjects With Neovascular Age Related Macular Degeneration. | ||